zaloblideg
Generic: Zaloblideg
zaloblideg: sourced relationships with 1 company · 1 clinical trial tracked.
zaloblideg evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect zaloblideg to ARVN; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could zaloblideg → ARVN affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| ARVINAS, INC. (ARVN) Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma… | Phase 1 |
Clinical Trial Registry Records (1)
A Phase 1 First in Human Study of ARV-393 in Adult Participants With Advanced Non-Hodgkin's Lymphoma
Primary endpoint: Incidence of Dose Limiting Toxicities During First 28 Days
Interventionalopen329 targetStarted 2024-09Completion 2028-0321 sites · Australia, Canada, Denmark, Spain…Arvinas Inc.
Frequently asked questions
Which companies have sourced relationships with zaloblideg?
zaloblideg has dated SEC/FDA relationship records for ARVINAS, INC..
How many clinical trials involve zaloblideg?
BioSniper tracks 1 clinical trial involving zaloblideg.